The ongoing development of faster acting prandial insulins: A Review of Recent Trials (https://doi.org/10.1111/dom.13963)

Abstract

This is a nice review article & update by Professors David Owens & Geremia Bolli covering the latest developments with novel, faster acting prandial insulins. Although the development of insulin lispro, aspart and glulisine offered an earlier onset of action and better postprandial glucose control, these insulin analogues still do not fully match the physiological profile of endogenous insulin in the systemic circulation following a meal. Thus, second-generation, even faster acting insulins have emerged in the form of faster-acting aspart, ultra-rapid lispro and BioChaperone lispro. A number of clinical trials with these agents have already been published in DOM. Owens & Bolli review the phase 3 trials in type 1 and type 2 diabetes, in particular with faster-acting aspart and ultra-rapid lispro, to show further incremental improvements in postprandial glycemic control.